Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about ALLERGAN PLC
12:12pALLERGAN : abicipar pegol non-inferior to Lucentis, but increases inflammation
AQ
11:26aIRONWOOD PHARMACEUTICALS : Initiates Phase IIIb Study of Linaclotide in Adult Pa..
AQ
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
DJ
07/12ALLERGAN : Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
AQ
07/11ALLERGAN : Forbion raises EUR 270M, surpassing target for fourth fund
AQ
07/10ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
PR
07/06ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
AQ
06/28ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
PU
06/26ALLERGAN : to Report Second Quarter 2018 Earnings and Host Conference Call and W..
PR
06/18ALLERGAN : Continues Active Board Refreshment Process
AQ
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR I..
AQ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14ALLERGAN : Continues Active Board Refreshment Process
PR
06/13ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (..
PR
06/13ALLERGAN : Lawsuit Filed Against Allergan for Defectively Packaged Taytulla&trad..
AQ
06/13ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
AQ
06/12ALLERGAN : and Actress Shay Mitchell Join Forces to Inspire Women to Know Their ..
AQ
06/11ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
PU
06/08JM SMUCKER : Market movers
AQ
06/07JM SMUCKER : NXP Semiconductors and Allergan rise; Smucker slips
AQ
06/07ALLERGAN : and Actress Shay Mitchell Join Forces to Inspire Women to Know Their ..
PR
06/07CARL ICAHN : sources
RE
06/06ALLERGAN : June is National Migraine and Headache Awareness Month
AQ
06/05ALLERGAN : Two Allergan shareholders call for split of chairman-CEO role
RE
06/05ALLERGAN : Responds to Public Shareholder Letter
PR
06/05ALLERGAN : Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients..
PR
05/31ALLERGAN : CoolSculpting And WeAllGrow Latina Network Host Discussion On The Per..
AQ
05/31ALLERGAN : to sell off women's health, infectious disease units
AQ
05/31ALLERGAN : CoolSculpting® And #WeAllGrow Latina Network Host Discussion On The P..
PU
05/30ALLERGAN : to sell women's health, infectious disease units
RE
05/30ALLERGAN : Issues Nationwide Voluntary Recall of TAYTULLA Softgel Capsules 1mg/2..
AQ
05/29ALLERGAN : Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/..
PR
05/24ALLERGAN : BioCentury - Aptinyx proposes $80M IPO
AQ
05/22ALLERGAN : Exercises Option to Acquire Compound from Aptinyx Discovery Platform ..
PR
05/18FDA approves Aimovig as first CGRP inhibitor for migraines
AQ
05/17ALLERGAN PLC : Ex-dividend day for
FA
05/16ALLERGAN : to Present at the Bernstein Strategic Decisions Conference
PR
05/16Evolus investors frown as FDA declines to approve Botox rival
RE
05/15Florida and Texas Are Among Latest States to Sue Opioid Painkiller Companies
DJ
05/15Pay, Performance Often at Odds -- WSJ
DJ
05/14CEO Pay and Performance Don't Match Up
DJ
05/11ALLERGAN : to Present at the Bank of America Merrill Lynch Healthcare Conference
AQ
05/10ALLERGAN : Declares Second Quarter 2018 Cash Dividend of $0.72 Per Ordinary Shar..
AQ
05/09Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LIN..
AQ
05/09ALLERGAN : Botox Company Steers Ads Toward Men In Face of More Competition
AQ
05/08ALLERGAN : Recovery Intact for Teva Pharmaceuticals But Stock Dropped Anyway
AQ
05/08ALLERGAN : to Present Data from a Robust Mental Health Clinical Program at the A..
AQ
05/07ALLERGAN : to Present at the Bank of America Merrill Lynch Healthcare Conference
PR
05/04ALLERGAN : and Ironwood Launch Interactive Digital Destination During Irritable ..
AQ
05/04ALLERGAN : to Present at the Deutsche Bank 43rd Annual Health Care Conference
AQ
05/04Amgen says ICER underestimates migraine patient burden
AQ
05/03ALLERGAN : John Davidson Elected to Allergan Board of Directors
PR
05/03ALLERGAN : Declares Second Quarter 2018 Cash Dividend of $0.72 Per Ordinary Shar..
PR
05/03ALLERGAN : Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resol..
BU
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
05/03ALLERGAN : Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 B..
AQ
05/02ALLERGAN : to Present Data from a Robust Mental Health Clinical Program at the A..
PU
05/02Indivior's first-quarter profit slips, shares fall on top drug let-down
RE
05/02ALLERGAN : Announces Second Positive Phase 3 Clinical Trial for Ubrogepant-an Or..
AQ
05/02ALLERGAN : to Present New Data at the American College of Obstetrics and Gynecol..
AQ
05/01ALLERGAN : to Present at the Deutsche Bank 43rd Annual Health Care Conference
PR
05/01Pfizer first-quarter results miss estimates as key drug sales fall short
RE
05/01Pfizer first-quarter results miss estimates as key drug sales fall short
RE
04/30ALLERGAN : Here’s What Just Happened At Allergan
AQ
04/30ALLERGAN : CEO opposes fundamental shift in strategy, shares fall
RE
04/30ALLERGAN : CEO opposes fundamental shift in strategy, shares fall
RE
04/30ALLERGAN CEO : large deal would be an unlikely outcome of review
RE
04/30ALLERGAN : Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 B..
PR
04/27ALLERGAN : Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an..
PR
04/26ALLERGAN : to Present New Data at the American College of Obstetrics and Gynecol..
PU
04/26ALLERGAN : Presents Data at the Annual Meeting of the Association of Research in..
PR
04/26ALLERGAN : Does Not Intend to Make an Offer for Shire plc; Strategic Review Cont..
AQ
04/26ALLERGAN : Issues Statement Regarding Press Speculation on its Strategic Review
AQ
04/26ALLERGAN : Showcases Leadership in Neurosciences with 25 Presentations at the Am..
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 15 306 M
EBIT 2018 7 381 M
Net income 2018 -1 152 M
Debt 2018 23 173 M
Yield 2018 1,58%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,41x
EV / Sales 2019 5,10x
Capitalization 59 628 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 207 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC7.51%59 628
JOHNSON & JOHNSON-8.53%342 779
PFIZER3.98%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.09%169 328